Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other Non-Current Liabilities: 2017-2025

Historic Other Non-Current Liabilities for Seres Therapeutics (MCRB) over the last 8 years, with Sep 2025 value amounting to $2.0 million.

  • Seres Therapeutics' Other Non-Current Liabilities rose 12.96% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 12.96%. This contributed to the annual value of $1.8 million for FY2024, which is 12.90% up from last year.
  • Latest data reveals that Seres Therapeutics reported Other Non-Current Liabilities of $2.0 million as of Q3 2025, which was up 3.07% from $2.0 million recorded in Q2 2025.
  • Seres Therapeutics' Other Non-Current Liabilities' 5-year high stood at $11.5 million during Q4 2021, with a 5-year trough of $777,000 in Q1 2021.
  • For the 3-year period, Seres Therapeutics' Other Non-Current Liabilities averaged around $1.8 million, with its median value being $1.8 million (2024).
  • In the last 5 years, Seres Therapeutics' Other Non-Current Liabilities spiked by 1,046.06% in 2021 and then tumbled by 88.28% in 2022.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Other Non-Current Liabilities stood at $11.5 million in 2021, then plummeted by 87.46% to $1.4 million in 2022, then grew by 12.90% to $1.6 million in 2023, then increased by 12.90% to $1.8 million in 2024, then grew by 12.96% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.0 million for Q2 2025, and $1.9 million during Q1 2025.